Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 33304 [2011-14202]
Download as PDF
<![CDATA[
33304
Federal Register / Vol. 76, No. 110 / Wednesday, June 8, 2011 / Notices
laboratories. The survey will be funded
in full by the Office of Surveillance,
Epidemiology, and Laboratory Services
(OSELS) of the Centers for Disease
Control and Prevention (CDC). Influenza
epidemics usually cause an average
more than 200,000 hospitalizations and
36,000 deaths per year in the U.S.
Respiratory illnesses caused by
influenza viruses are not easily
differentiated from other respiratory
infections based solely on symptoms.
Also influenza viruses may adversely
affect different subpopulations. The
effective use of rapid influenza
diagnostic testing practices is an
important component of the differential
diagnosis of influenza-like-illness in
both inpatient and outpatient treatment
facilities. Test results are used for
making decisions about antiviral vs.
antibiotic use, and in making admission
or discharge decisions. In many cases,
rapid influenza tests are the only tests
that can provide results while the
patient is still present in the facility.
Thus, the appropriate use of the tests,
and interpretation of test results is
critical to the treatment and control of
influenza. More than a dozen rapid tests
emergency departments and treatment
facilities and health departments, and
what quality assurance practices are
used will guide future efforts of the CDC
to develop appropriate influenza testing
guidelines and sector-specific training
materials for clinicians and improve
health outcomes of the American
public.
The survey covers basic laboratory
demographic characteristics, specimen
collection and processing, testing
practices, reporting of results to
emergency departments and other
treatment facilities, reporting results to
health departments, quality assurance
practices, and methods of receiving
updated influenza-related information.
The majority of the questions request
information about laboratory influenza
testing practices.
To date, no systematic study has been
conducted to investigate how
laboratories use these tests, how they
report results, or how they interact with
outpatient treatment facilities. The
survey will be conducted on a national
sample of clinical laboratories. There
are no costs to respondents except their
time.
have been approved by the U.S. Food
and Drug Administration and are in
widespread use. The reliability of rapid
influenza tests is influenced by the
individual test product used and the
setting. Reported sensitivities range
from 10–75%; while the median
specificities reported are 90–95%. Other
factors influencing accuracy are the
stage (or duration) of illness when the
diagnostic specimen is collected, type
and adequacy of the specimen collected,
variability in user technique for
specimen collection or assay
performance, and disease activity in the
community. Given these and other
collective findings, it is imperative for
public health and for response planning
that CDC develops sector-specific
guidance and effective outreach to the
clinicians on appropriate use of RIDT in
their practices.
Previous studies by CDC of outpatient
facilities showed that clinical
laboratories usually perform the rapid
tests for emergency departments, and
provide results for both inpatient and
outpatient treatment. Thus,
understanding the use of rapid
influenza testing in clinical laboratories,
how the laboratories report results to
ESTIMATED ANNUALIZED BURDEN HOURS
No. of
respondents
No. of
responses per
respondent
Avg. burden
per response
(in hrs)
Total burden
(in hrs)
Type of respondents
Form name
Clinical Laboratory Supervisors ........
Survey of Rapid Influenza Diagnostic Test Practices in Clinical
Laboratories.
600
1
30/60
300
Total ...........................................
..........................................................
........................
........................
........................
300
Dated: June 1, 2011.
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2011–14147 Filed 6–7–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
sroberts on DSK5SPTVN1PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below
concerns Strategies to Improve
Vaccination Coverage of Children in
Child Care Centers (CCCs) and
Preschools, Funding Opportunity
Announcement (FOA) IP11–006;
Strategies to Increase Health Care
VerDate Mar<15>2010
21:51 Jun 07, 2011
Jkt 223001
Providers Use of Population-Based
Immunization Information Systems,
FOA IP11–008; Effectiveness in an
Intervention to Promote a Targeted
Vaccination program in the
Obstetrician-Gynecologist Setting, FOA
IP11–009; initial review.
Correction: The notice was published
in the Federal Register on April 29,
2011, Volume 76, Number 83, Pages
24031. The place should read as
follows:
Place: Holiday Inn Decatur
Conference Center, 130 Clairemont
Avenue, Decatur, Georgia 30030,
Telephone: (404)371–0204.
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road, NE., Mailstop E00,
Atlanta, Georgia 30333, Telephone:
(404) 498–2293.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
PO 00000
Frm 00114
Fmt 4703
Sfmt 9990
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: May 27, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2011–14202 Filed 6–7–11; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\08JNN1.SGM
08JNN1
]]>Agencies
[Federal Register Volume 76, Number 110 (Wednesday, June 8, 2011)]
[Notices]
[Page 33304]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-14202]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The meeting announced below concerns Strategies to Improve
Vaccination Coverage of Children in Child Care Centers (CCCs) and
Preschools, Funding Opportunity Announcement (FOA) IP11-006; Strategies
to Increase Health Care Providers Use of Population-Based Immunization
Information Systems, FOA IP11-008; Effectiveness in an Intervention to
Promote a Targeted Vaccination program in the Obstetrician-Gynecologist
Setting, FOA IP11-009; initial review.
Correction: The notice was published in the Federal Register on
April 29, 2011, Volume 76, Number 83, Pages 24031. The place should
read as follows:
Place: Holiday Inn Decatur Conference Center, 130 Clairemont
Avenue, Decatur, Georgia 30030, Telephone: (404)371-0204.
Contact Person for More Information: Gregory Anderson, M.S.,
M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road, NE.,
Mailstop E00, Atlanta, Georgia 30333, Telephone: (404) 498-2293.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Dated: May 27, 2011.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2011-14202 Filed 6-7-11; 8:45 am]
BILLING CODE 4163-18-P
